# FDA Grants Accelerated Approval to Vera Therapeutics TRUTAKNA for IgA Nephropathy

> fda · REPORTED · 2026-07-07

The FDA granted accelerated approval to Vera Therapeutics' TRUTAKNA (atacicept-vymj) on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression, based on a 46% reduction from baseline in proteinuria and a statistically significant 42% reduction versus placebo at 36 weeks in the ORIGIN 3 trial. This approval marks Vera's transition to a commercial-stage company in kidney disease.

About Vera Therapeutics: Vera Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases, with TRUTAKNA being a dual BAFF and APRIL inhibitor targeting IgA nephropathy.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://www.globenewswire.com/news-release/2026/07/07/3323532/0/en/vera-therapeutics-receives-fda-accelerated-approval-for-trutakna-for-adult-patients-with-primary-iga-nephropathy.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.